Albert Bourla: Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at ASCO24

Albert Bourla, Chairman and Chief Executive Officer of Pfizer, shared a post on LinkedIn:

“We’re making significant progress in the fight against lung cancer. Today at ASCO24, we shared important results from our Phase 3 clinical trial evaluating treatments for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). After five years of median follow-up, one of our treatments showed unprecedented progression-free survival, with 60% of patients alive without disease worsening.

Lung cancer is the #1 cause of cancer-related death around the world. We have spent years at Pfizer working on developing potential solutions that can help people with cancer live better and longer lives. These results represent Pfizer’s commitment to advancing outcomes for patients.”

Read further.
Source: Albert Bourla/LinkedIn